Research analysts at Citigroup Inc. began coverage on shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in a report released on Wednesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $10.00 price target on the biopharmaceutical company’s stock. Citigroup Inc.’s target price indicates a potential upside of 65.29% from the stock’s current price.

INO has been the subject of a number of other research reports. Aegis restated a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Maxim Group upped their price objective on shares of Inovio Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, May 24th. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, July 7th. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 15th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. Inovio Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $19.80.

Shares of Inovio Pharmaceuticals (INO) traded down 0.49% on Wednesday, hitting $6.05. The stock had a trading volume of 929,728 shares. The firm has a 50 day moving average price of $5.69 and a 200 day moving average price of $6.70. Inovio Pharmaceuticals has a one year low of $5.28 and a one year high of $9.86. The company’s market capitalization is $545.87 million.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The business had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. During the same quarter in the prior year, the company earned ($0.26) EPS. The firm’s quarterly revenue was up 229.2% on a year-over-year basis. On average, equities research analysts predict that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Inovio Pharmaceuticals, Inc. (INO) Earns Buy Rating from Analysts at Citigroup Inc.” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/10/inovio-pharmaceuticals-inc-ino-earns-buy-rating-from-analysts-at-citigroup-inc.html.

A number of hedge funds have recently added to or reduced their stakes in INO. Wasatch Advisors Inc. increased its holdings in Inovio Pharmaceuticals by 43.6% during the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after purchasing an additional 793,306 shares in the last quarter. Vanguard Group Inc. increased its holdings in Inovio Pharmaceuticals by 7.9% during the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after purchasing an additional 226,861 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth about $1,411,000. GSA Capital Partners LLP bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth about $1,035,000. Finally, Virtu KCG Holdings LLC bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth about $556,000. Hedge funds and other institutional investors own 24.83% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.